2025
Immunotherapy for Renal Cell Carcinoma—What More is to Come?
Yochum Z, Braun D. Immunotherapy for Renal Cell Carcinoma—What More is to Come? Targeted Oncology 2025, 20: 467-483. PMID: 40208564, DOI: 10.1007/s11523-025-01143-7.Peer-Reviewed Original ResearchConceptsICI-based regimensRenal cell carcinomaImmune checkpoint inhibitorsMetastatic renal cell carcinomaVEGFR-TKIsVascular endothelial growth factor receptor tyrosine kinase inhibitorsGrowth factor receptor tyrosine kinase inhibitorsClinical trialsAnti-PD-1 therapyAntitumor T-cell immunityImprove T-cell activationReceptor tyrosine kinase inhibitorsTreatment of renal cell carcinomaDurability of treatment responseFirst-line therapyPatient outcomesT cell immunityTyrosine kinase inhibitorsFDA-approved agentsT cell activationInnovative treatment strategiesCheckpoint inhibitorsCell carcinomaImprove patient outcomesTumor microenvironment
2024
TIGIT expression in renal cell carcinoma infiltrating T cells is variable and inversely correlated with PD-1 and LAG3
Perales O, Jilaveanu L, Adeniran A, Su D, Hurwitz M, Braun D, Kluger H, Schoenfeld D. TIGIT expression in renal cell carcinoma infiltrating T cells is variable and inversely correlated with PD-1 and LAG3. Cancer Immunology, Immunotherapy 2024, 73: 192. PMID: 39105820, PMCID: PMC11303630, DOI: 10.1007/s00262-024-03773-8.Peer-Reviewed Original ResearchConceptsRenal cell carcinomaRenal cell carcinoma tumorsT cellsTIGIT expressionCheckpoint inhibitorsPD-1Likelihood of response to therapyTumor-infiltrating T cellsCD3+ T cellsRenal cell carcinoma metastasisTreatment of renal cell carcinomaImmune checkpoint inhibitorsInfiltrating T cellsPurposeImmune checkpoint inhibitorsResponse to therapyT cell immunoglobulinCD3+ levelsMetastatic RCC specimensAdjacent normal renal tissuesNormal renal tissuesQuantitative immunofluorescence analysisCell carcinomaResistant diseasePotential therapeutic targetTissue microarray45 INTerpath-004: A phase 2, randomized, double-blind study of pembrolizumab with V940 (mRNA-4157) or placebo in the adjuvant treatment of renal cell carcinoma
Choueiri T, Powles T, Braun D, Fong L, George D, Haas N, McDermott D, Shuch B, Gurney H, Meehan R, Posadas T, Wu S, Elfiky A, Motzer R. 45 INTerpath-004: A phase 2, randomized, double-blind study of pembrolizumab with V940 (mRNA-4157) or placebo in the adjuvant treatment of renal cell carcinoma. The Oncologist 2024, 29: s15-s15. PMCID: PMC11301864, DOI: 10.1093/oncolo/oyae181.022.Peer-Reviewed Original ResearchRenal cell carcinomaWeeks prior to randomizationAdverse eventsAdjuvant treatmentCell carcinomaResection of metastatic lesionsAdjuvant treatment of patientsPD-1 inhibitor pembrolizumabIncreased risk of recurrenceAdjuvant treatment of renal cell carcinomaTreatment of renal cell carcinomaActivity of pembrolizumabStage III/IV melanomaStudy of pembrolizumabDisease-free survivalMetastasis-free survivalPhase 2 trialRisk of recurrenceDouble-blind studyTreatment of patientsNovel combination strategiesDose of treatmentAdjuvant pembrolizumabAdjuvant settingInhibitor pembrolizumabEpigenomic signatures of sarcomatoid differentiation to guide the treatment of renal cell carcinoma
El Zarif T, Semaan K, Eid M, Seo J, Garinet S, Davidsohn M, Sahgal P, Fortunato B, Canniff J, Nassar A, Abou Alaiwi S, Bakouny Z, Lakshminarayanan G, Savignano H, Lyons K, Matar S, Ali A, Saad E, Saliby R, Cordeiro P, Zhang Z, El Ahmar N, Laimon Y, Labaki C, Shah V, Freeman D, O'Toole J, Lee G, Hwang J, Pomerantz M, Signoretti S, Van Allen E, Xie W, Berchuck J, Viswanathan S, Braun D, Choueiri T, Freedman M, Baca S. Epigenomic signatures of sarcomatoid differentiation to guide the treatment of renal cell carcinoma. Cell Reports 2024, 43: 114350. PMID: 38870013, PMCID: PMC11929466, DOI: 10.1016/j.celrep.2024.114350.Peer-Reviewed Original ResearchImmune checkpoint inhibitorsRenal cell carcinomaSarcomatoid differentiationCell carcinomaResponse to immune checkpoint inhibitorsGene regulatory programsAssociated with poor survivalTreatment of renal cell carcinomaLow diagnostic yieldRandomized clinical trialsCheckpoint inhibitorsTumor histologyEpigenomic signaturesTranscription factor FOSL1Healthy volunteersPatient plasmaPoor survivalLiquid biopsyFOSL1 expressionClinical trialsProfiling histone modificationsDiagnostic approachImprove outcomesRegulatory programsPlasma samplesSLAMF7+ CD8+ T cells exhibit decreased anti-tumor responses in renal cell carcinoma
Wirth L, Hugaboom M, Street K, Ruthen N, Jegede O, Schindler N, McDermott D, Plimack E, Sosman J, Haas N, Hurwitz M, Hammers H, Signoretti S, Atkins M, Wu C, Braun D. SLAMF7+ CD8+ T cells exhibit decreased anti-tumor responses in renal cell carcinoma. The Journal Of Immunology 2024, 212: 1491_5876-1491_5876. DOI: 10.4049/jimmunol.212.supp.1491.5876.Peer-Reviewed Original ResearchCD8+ T cellsImmune-checkpoint inhibitorsRenal cell carcinomaCD8+ T-cell effector functionT cell effector functionT cellsCell carcinomaResistance to immune-checkpoint inhibitorsEffector functionsPopulation of CD8+ T cellsCD3+ T cellsTreatment of renal cell carcinomaHealthy human PBMCTumor-infiltrating lymphocytesAnti-tumor responsesPatient T cellsReduction of pro-inflammatory cytokinesAnti-tumor functionPro-inflammatory cytokinesSingle-cell transcriptome analysisNivolumab monotherapySLAMF7 expressionClinical benefitGranzyme BIFN-gThe Role of Targeted Radiation Therapy in the Treatment of Renal Cell Carcinoma
Lee A, Runcie K, Yu J. The Role of Targeted Radiation Therapy in the Treatment of Renal Cell Carcinoma. Kidney Cancer 2024, 8: 45-50. DOI: 10.3233/kca-230020.Peer-Reviewed Original ResearchStereotactic body radiotherapyTreatment of renal cell carcinomaRenal cell carcinomaCell carcinomaCombination of stereotactic body radiotherapyUse of stereotactic body radiotherapyNovel systemic agentsTargeted radiation therapyTreatment of RCCRadiation therapySystemic agentsCarcinomaTreatmentRCCRadiotherapyRadiation technologyIncreased useTherapy
2019
Radiation Therapy for Renal Cell Carcinoma
Choi R, Yu J. Radiation Therapy for Renal Cell Carcinoma. Kidney Cancer 2019, 3: 1-6. DOI: 10.3233/kca-180040.Peer-Reviewed Original ResearchRenal cell carcinomaTreatment of renal cell carcinomaStereotactic ablative radiotherapyRadiation therapyCell carcinomaAdjuvant treatment of renal cell carcinomaAblative radiotherapyAdjuvant treatmentTreatment optionsHigh dosesTherapyCarcinomaTargets of diseaseTreatmentRT’s roleRadiotherapyCancerDose
2009
Cost implications of IV versus oral anti-angiogenesis therapies in patients with advanced renal cell carcinoma: retrospective claims database analysis*
Duh M, Dial E, Choueiri T, Fournier A, Antras L, Rodermund D, Neary M, Oh W. Cost implications of IV versus oral anti-angiogenesis therapies in patients with advanced renal cell carcinoma: retrospective claims database analysis*. Current Medical Research And Opinion 2009, 25: 2081-2090. PMID: 19586325, DOI: 10.1185/03007990903084800.Peer-Reviewed Original ResearchConceptsPer-patient per-monthRenal cell carcinomaAngiogenesis inhibitorsAI therapyCell carcinomaUS commercial health insurance claims databaseAdvanced renal cell carcinomaIV therapyAI groupTreatment of renal cell carcinomaProgression-free survivalTreated with sunitinibBaseline clinical characteristicsAnti-angiogenesis therapyRetrospective claims databaseHealth insurance claims databaseInsurance Claims DatabaseIncremental total costBevacizumab patientsBevacizumab groupOral therapyCost of treatmentBevacizumabClinical characteristicsOff-labelCost implications of intravenous bevacizumab treatment in patients with renal cell carcinoma (RCC): A retrospective claims database analysis
Dial E, Duh M, Fournier A, Antras L, Rodermund D, Neary M, Oh W. Cost implications of intravenous bevacizumab treatment in patients with renal cell carcinoma (RCC): A retrospective claims database analysis. Journal Of Clinical Oncology 2009, 27: 5112-5112. DOI: 10.1200/jco.2009.27.15_suppl.5112.Peer-Reviewed Original ResearchRenal cell carcinomaAI therapyAngiogenesis inhibitorsUS commercial health insurance claims databaseIV therapyAI groupTreatment of renal cell carcinomaCost of bevacizumabIntravenous bevacizumab treatmentTreated with sunitinibRetrospective claims database analysisHealth insurance claims databaseClaims database analysisInsurance Claims DatabaseTotal medical costsBevacizumab groupBevacizumab patientsBevacizumab treatmentCell carcinomaBevacizumabTreatment initiationSunitinibSorafenibTreatment periodOral administration
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply